Cargando…
A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus
Nano-particles have been combined with antibiotics in recent studies to overcome multidrug-resistant bacteria. Here, we synthesized a nano-material in which Ag nano-particles were assembled with a ZnO nano-structure to form an Ag-ZnO (AZO) nano-composite at low temperature. This material was combine...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558003/ https://www.ncbi.nlm.nih.gov/pubmed/32887402 http://dx.doi.org/10.3390/pharmaceutics12090841 |
_version_ | 1783594542345224192 |
---|---|
author | Naskar, Atanu Lee, Sohee Lee, Yunhee Kim, Semi Kim, Kwang-sun |
author_facet | Naskar, Atanu Lee, Sohee Lee, Yunhee Kim, Semi Kim, Kwang-sun |
author_sort | Naskar, Atanu |
collection | PubMed |
description | Nano-particles have been combined with antibiotics in recent studies to overcome multidrug-resistant bacteria. Here, we synthesized a nano-material in which Ag nano-particles were assembled with a ZnO nano-structure to form an Ag-ZnO (AZO) nano-composite at low temperature. This material was combined with erythromycin (Ery), an antibiotic effective towards gram-positive bacteria, using three different approaches (AZO + Ery (AZE) [centrifuged (AZE1), used separately after 1-h gap (AZE2), without centrifugation (AZE3)]) to prepare a nano-antibiotic against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). X-ray diffraction analysis and transmission electron microscopy confirmed the presence of Ag nano-particles and ZnO nano-structure. The elemental and chemical state of the elements present in the AZO nano-composite were assessed by X-ray photoelectron spectroscopy. The antibacterial activity of AZE samples against both Escherichia coli and S. aureus strains including MRSA was evaluated in antibacterial and morphological analyses. The AZE3 sample showed greater antibacterial activity than the other samples and was comparable to erythromycin. AZE3 was ~20-fold less prone to developing bacterial resistance following multiple exposures to bacteria compared to erythromycin alone. The AZE3 nano-composite showed good biocompatibility with 293 human embryonic kidney cells. Our newly synthesized nano-platform antibiotics may be useful against multidrug-resistant gram-positive bacteria. |
format | Online Article Text |
id | pubmed-7558003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75580032020-10-22 A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus Naskar, Atanu Lee, Sohee Lee, Yunhee Kim, Semi Kim, Kwang-sun Pharmaceutics Article Nano-particles have been combined with antibiotics in recent studies to overcome multidrug-resistant bacteria. Here, we synthesized a nano-material in which Ag nano-particles were assembled with a ZnO nano-structure to form an Ag-ZnO (AZO) nano-composite at low temperature. This material was combined with erythromycin (Ery), an antibiotic effective towards gram-positive bacteria, using three different approaches (AZO + Ery (AZE) [centrifuged (AZE1), used separately after 1-h gap (AZE2), without centrifugation (AZE3)]) to prepare a nano-antibiotic against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). X-ray diffraction analysis and transmission electron microscopy confirmed the presence of Ag nano-particles and ZnO nano-structure. The elemental and chemical state of the elements present in the AZO nano-composite were assessed by X-ray photoelectron spectroscopy. The antibacterial activity of AZE samples against both Escherichia coli and S. aureus strains including MRSA was evaluated in antibacterial and morphological analyses. The AZE3 sample showed greater antibacterial activity than the other samples and was comparable to erythromycin. AZE3 was ~20-fold less prone to developing bacterial resistance following multiple exposures to bacteria compared to erythromycin alone. The AZE3 nano-composite showed good biocompatibility with 293 human embryonic kidney cells. Our newly synthesized nano-platform antibiotics may be useful against multidrug-resistant gram-positive bacteria. MDPI 2020-09-02 /pmc/articles/PMC7558003/ /pubmed/32887402 http://dx.doi.org/10.3390/pharmaceutics12090841 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Naskar, Atanu Lee, Sohee Lee, Yunhee Kim, Semi Kim, Kwang-sun A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus |
title | A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus |
title_full | A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus |
title_fullStr | A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus |
title_full_unstemmed | A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus |
title_short | A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus |
title_sort | new nano-platform of erythromycin combined with ag nano-particle zno nano-structure against methicillin-resistant staphylococcus aureus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558003/ https://www.ncbi.nlm.nih.gov/pubmed/32887402 http://dx.doi.org/10.3390/pharmaceutics12090841 |
work_keys_str_mv | AT naskaratanu anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT leesohee anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT leeyunhee anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT kimsemi anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT kimkwangsun anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT naskaratanu newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT leesohee newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT leeyunhee newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT kimsemi newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus AT kimkwangsun newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus |